retatrutide phase 3 trials Shows 28.3% Weight Loss in Obesity Trial Retatrutide produces up to 30.3%

Control your appetite with weekly Mounjaro injection Point 1: Works to suppress appetite and support weight loss Point 2: Effects last with just one subcutaneous injection per week Point 3: Self-injection at home means no clinic visits required Interpretation and counseling services are free of charge

If the solution does not clear after refrigerating and re-swirling, discard the vial aggregated peptide cannot be de-aggregated

Max Accredited Investor Limit: 249 This communication is from Alumni Ventures, a for-profit venture capital company that is not affiliated with or endorsed by any school

Just the facts